119 related articles for article (PubMed ID: 19133981)
1. Decitabine is an effective treatment of idiopathic myelofibrosis.
Danilov AV; Relias V; Feeney DM; Miller KB
Br J Haematol; 2009 Apr; 145(1):131-2. PubMed ID: 19133981
[No Abstract] [Full Text] [Related]
2. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
3. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Liu Y; Tabarroki A; Billings S; Visconte V; Rogers HJ; Hasrouni E; Englehaupt R; Kalaycio M; Sekeres MA; Saunthararajah Y; Tiu RV
Leuk Lymphoma; 2014 Feb; 55(2):447-9. PubMed ID: 23647061
[No Abstract] [Full Text] [Related]
4. Decitabine. MGI Pharma Inc/SuperGen Inc.
Arthur C
IDrugs; 2004 Dec; 7(12):1113-32. PubMed ID: 15599805
[TBL] [Abstract][Full Text] [Related]
5. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.
Steensma DP; Friday BB
Leuk Lymphoma; 2007 Aug; 48(8):1628-9. PubMed ID: 17701595
[No Abstract] [Full Text] [Related]
6. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
7. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Silverman LR; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
9. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Tabarroki A; Saunthararajah Y; Visconte V; Cinalli T; Colaluca K; Rogers HJ; Sekeres MA; Duong HK; Stein BL; Tiu RV
Leuk Lymphoma; 2015 Feb; 56(2):497-9. PubMed ID: 24766471
[No Abstract] [Full Text] [Related]
10. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
Carella AM
Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976
[No Abstract] [Full Text] [Related]
11. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
13. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
Sekeres MA; Steensma DP
J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302
[No Abstract] [Full Text] [Related]
14. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Kuykendall JR
Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplasia, megakaryocytes, and methylation.
Steensma DP
Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
[No Abstract] [Full Text] [Related]
16. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
[TBL] [Abstract][Full Text] [Related]
17. Drug therapy for myelodysplastic syndrome: building evidence for action.
Tefferi A; Letendre L
Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
[No Abstract] [Full Text] [Related]
18. DNA methylation: its role in cancer development and therapy.
Kurkjian C; Kummar S; Murgo AJ
Curr Probl Cancer; 2008; 32(5):187-235. PubMed ID: 18926282
[No Abstract] [Full Text] [Related]
19. Clinical effectiveness of decitabine in severe sickle cell disease.
Saunthararajah Y; Molokie R; Saraf S; Sidhwani S; Gowhari M; Vara S; Lavelle D; DeSimone J
Br J Haematol; 2008 Apr; 141(1):126-9. PubMed ID: 18324975
[No Abstract] [Full Text] [Related]
20. Decitabine has promising clinical activity in chronic myeloid leukemia.
Expert Rev Anticancer Ther; 2002 Dec; 2(6):620-1. PubMed ID: 12503205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
